Diabetes &
GLP-1 Drug
Assays
Validated competitive ELISA kits for GLP-1 receptor agonist and insulin analog pharmacokinetic monitoring, plus immunogenicity (ADA/nAb) assays. Includes KOD1027 the world's first and only commercial Tirzepatide ELISA. Species-independent, ISO 13485 manufactured, EMA/FDA-validated.
Browse All Assay Kits Assay Science OverviewGLP-1 Receptor Agonist Drug ELISA
Competitive immunoassay kits for quantitative measurement of GLP-1 agonist drug concentrations in serum, plasma, and cell culture media. All kits use recombinant receptor protein or high-specificity anti-drug antibodies as capture agents. Species-independent valid for human clinical and rat/mouse preclinical samples with the same kit.
World's first and only commercial ELISA for Tirzepatide. KOD1027 uses recombinant human GLP-1R protein (HEK293-expressed, =98% HPLC purity) as the capture antigen in a competitive format. HRP-conjugated synthetic Tirzepatide analog competes with sample Tirzepatide for receptor binding.
Cross-reactivity: Semaglutide not detected. Exenatide partial (confirm specificity for mixed-agent studies). Range: 31.34,000 ng/mL. Validated: serum, EDTA plasma, heparin plasma, cell culture supernatant. CV <10% intra-assay, <13% inter-assay. Spike recovery: 92107%.
Acylated GLP-1 analog with C18 fatty diacid chain enabling albumin binding and ~7-day half-life. The active ingredient of Ozempic (T2DM), Wegovy (obesity), and Rybelsus (oral formulation). Leading global GLP-1 agonist by market share. KBI5030 provides specific quantification without Liraglutide or Exenatide cross-reactivity.
Range: 7.81,000 ng/mL. Validated: serum, plasma. CV <12%. Recovery 88110%. Suitable for comparative PK studies between semaglutide originator and biosimilar candidates.
C16 fatty acid-acylated GLP-1 analog with ~13-hour half-life. First once-daily GLP-1 agonist approved for T2DM (Victoza) and obesity (Saxenda at higher dose). Multiple biosimilars entering development globally. KBI5020 validated for PK monitoring in human clinical trials and rat/mouse preclinical studies.
Range: 7.81,000 ng/mL. Validated: serum, plasma. No cross-reactivity with endogenous GLP-1. Pair with KBN5020 anti-Liraglutide nAb ELISA for full immunogenicity package.
Synthetic version of exendin-4, a peptide from Gila monster saliva with 53% homology to human GLP-1 but 10 higher GLP-1R binding affinity. Available as twice-daily (Byetta) and weekly extended-release (Bydureon BCise). KBI5013 specific for exenatide does not detect liraglutide or semaglutide.
Exendin-4 derivative with C-terminal modification extending GLP-1R selectivity. Once-daily injection (Adlyxin/Lyxumia). Particularly studied for postprandial glucose control via gastric emptying delay. KBI5021 competitive ELISA validated for clinical PK and rat/mouse preclinical studies.
Insulin Analog Drug ELISA
Competitive ELISA kits specific to engineered insulin analogs do not cross-react with endogenous human insulin. Essential for measuring exogenous drug in clinical samples where endogenous insulin is present. Species-independent. All kits include paired ADA ELISA for immunogenicity assessment.
Long-acting basal analog with two arginine residues added at B-chain C-terminus and A21 asparagine replaced by glycine. Shifts isoelectric point to pH 6.7, causing precipitation at physiological pH for sustained depot absorption. ~24h flat action profile. First long-acting analog approved. Now with biosimilar competitors (Basaglar, Semglee, Rezvoglar). Pair drug ELISA (KBI2001) with anti-Glargine ADA ELISA (KBI9001) for complete PK/immunogenicity assessment.
Rapid-acting mealtime analog B28 proline replaced by aspartic acid, reducing self-association and enabling faster subcutaneous absorption (peak 4050 min vs 23h for human insulin). Used as mealtime insulin and in closed-loop insulin delivery systems. Major biosimilar competition with Fiasp (ultra-fast formulation). KBI2002 drug ELISA has no cross-reactivity with human insulin. Pair with KBI9002 ADA ELISA.
First approved rapid-acting analog B28 lysine and B29 proline positions reversed (Lys-Pro), disrupting hydrophobic surface and preventing hexamer formation. Faster onset than human regular insulin. Multiple biosimilars including Admelog and insulin lispro-aabc (Lyumjev ultra-rapid). KBI2003 competitive ELISA specific to Lispro structure with no human insulin interference. Pair with KBI9003 ADA ELISA.
Ultra-long-acting basal analog B30 threonine deleted, C16 fatty diacid attached via glutamic acid linker at B29 lysine. Forms soluble multi-hexamer depot at injection site with gradual monomeric release. >42h action profile, once-daily or even 3/week dosing. Currently no approved biosimilar in most markets, but development underway. KBI2005 competitive ELISA validated for PK studies in clinical and preclinical settings.
Anti-Drug Antibody (ADA) & Neutralising Antibody ELISA
Immunogenicity assessment is a regulatory requirement for all biologic drugs. Two distinct assay formats serve different immunogenicity objectives understanding which to use is critical for regulatory submissions.
Used for GLP-1 agonist immunogenicity. The drug is coated as capture AND as HRP-conjugate. Patient ADA that can bind both forms (bridging antibodies) generate a positive signal. This bridging format is drug-tolerant designed to detect ADA even in the presence of excess circulating drug. Available for Semaglutide (KBI9030) and Liraglutide (KBN5020).
Result interpretation: sample OD vs cut-off value (mean of negative controls + 2SD). Result reported as positive/negative for immunogenicity.
Used for insulin analog ADA detection. The drug (e.g. Glargine, Aspart, Lispro) is coated to the microplate as capture antigen. Patient-derived anti-drug IgG binds to coated drug, then is detected by HRP-anti-human IgG secondary antibody. Signal is directly proportional to ADA amount.
Result interpretation: sample OD vs Blank mean + 2SD cut-off. Report as positive/negative. Available: Anti-Glargine (KBI9001), Anti-Aspart (KBI9002), Anti-Lispro (KBI9003). Please verify catalog numbers with Krishgen technical team.
Diabetes & GLP-1 Assay Reference Table
Complete Krishgen ELISA portfolio for diabetes drug PK and immunogenicity. All kits validated: CV <15%, spike-recovery 85115%. CoA and validation reports on request.
| Catalog # | Target / Analyte | Brand / Application | Type | Format | Range | Species | Link |
|---|---|---|---|---|---|---|---|
| KOD1027 | TirzepatideDual GIP/GLP-1 agonist | MOUNJARO ZEPBOUND | World FirstDrug PK | Competitive | 31.34,000 ng/mL | Human / Rat / Mouse | View |
| KBI5030 | SemaglutideGLP-1 receptor agonist | OZEMPIC WEGOVY RYBELSUS | Drug PK | Competitive | 7.81,000 ng/mL | Human / Rat / Mouse | View |
| KBI9030 | Anti-Semaglutide nAbNeutralising antibody | Immunogenicity screening | nAb / ADA | Bridging | Qualitative +/- | Human | View |
| KBI5020 | LiraglutideGLP-1 receptor agonist | VICTOZA SAXENDA | Drug PK | Competitive | 7.81,000 ng/mL | Human / Rat / Mouse | View |
| KBN5020 | Anti-Liraglutide nAbNeutralising antibody | Immunogenicity screening | nAb / ADA | Bridging | Qualitative +/- | Human | View |
| KBI5013 | ExenatideExendin-4 GLP-1R agonist | BYETTA BYDUREON | Drug PK | Competitive | 7.8500 ng/mL | Human / Rat / Mouse | View |
| KBI5021 | LixisenatideExendin-4 derivative | ADLYXIN LYXUMIA | Drug PK | Competitive | 7.8500 ng/mL | Human / Rat / Mouse | View |
| KBI2001 | Insulin GlargineLong-acting basal analog | LANTUS TOUJEO | Drug PK | Competitive | 0.550 ng/mL | Human / Rat / Mouse | View |
| KBI9001 | Anti-Glargine ADAAnti-drug antibody | Immunogenicity screening | ADA ELISA | Qualitative indirect | Qualitative +/- | Human | View |
| KBI2002 | Insulin AspartRapid-acting mealtime analog | NOVOLOG NOVORAPID | Drug PK | Competitive | 0.550 ng/mL | Human / Rat / Mouse | View |
| KBI9002 | Anti-Aspart ADAVerify catalog number with team | Immunogenicity screening | ADA ELISA | Qualitative indirect | Qualitative +/- | Human | View |
| KBI2003 | Insulin LisproRapid-acting mealtime analog | HUMALOG Admelog | Drug PK | Competitive | 0.550 ng/mL | Human / Rat / Mouse | View |
| KBI9003 | Anti-Lispro ADAVerify catalog number with team | Immunogenicity screening | ADA ELISA | Qualitative indirect | Qualitative +/- | Human | View |
| KBI2005 | Insulin DegludecUltra-long-acting basal analog | TRESIBA | Drug PK | Competitive | 0.550 ng/mL | Human / Rat / Mouse | View |
Frequently Asked Questions
Yes. As of our last competitive landscape review, KOD1027 is the first and only commercially available Tirzepatide ELISA. Tirzepatide's unique dual GIP/GLP-1 receptor agonist structure meant existing GLP-1 assays were non-functional, requiring a new assay developed from a recombinant GLP-1R capture antigen.
Yes. All GLP-1 agonist and insulin analog drug ELISA are species-independent they detect the drug molecule, not an endogenous protein, so the same kit functions in human, rat, and mouse samples. No species-specific kit switching required across your development programme.
Need a Custom or Unlisted Assay
Can’t find your specific GLP-1 agent or insulin analog? Our technical team can develop custom drug ELISA and ADA assays within 8-12 weeks.